Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AGC Biologics Breaks Ground on New Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

AGC Biologics Breaks Ground on New Facility

Multipurpose facility at the CDMO’s Copenhagen, Denmark site will include a manufacturing building, an office building and a visitors center.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), broke ground on a new facility at its Copenhagen, Denmark site. This multipurpose facility will include a manufacturing building, an office building and a visitors center. The manufacturing building will be comprised of four levels holding approximately 8,000 square meters distributed across manufacturing, quality control laboratories, technical and warehouse areas. Around 250-300 new jobs will be created as a result of the expansion. Production will be based on genetically modified organisms, biosafety level 1, manufactured with single-use technology in clean rooms.
 
The biopharmaceuticals CDMO market continues to grow in double digits annually and the expansion allows AGC Biologics to strengthen its market position. This investment will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen. AGC’s other biologics facilities are in Seattle WA, Boulder CO and Chiba, Japan.
 
“We are excited to announce the groundbreaking of the new facility,” said Patricio Massera, CEO, AGC Biologics. “We are fully committed to understand and meet our customers’ needs, as we continuously seek to provide new capacity and new services.”
 
Andrea C. Porchia, Copenhagen site head, AGC Biologics, said, “We are now establishing a new state-of-the-art facility with a flexible and efficient set-up for biologic drug substance manufacturing. It will be a great facility and we are looking forward to making it available for existing and new customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics